Rager JE, Ring CL, Fry RC, Suh M, Proctor DM, Haws L, Harris MA, Thompson CM. 2017. High-Throughput Screening Data Interpretation in the Context of In Vivo Transcriptomic Responses to Oral Cr(VI) Exposure. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfx085

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol. 325:9-17.


Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 800-801:28-34.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic Responses in the Oral Cavity of F344 Rats and B6C3F1 Mice Following Exposure to Cr(VI): Implications for Risk Assessment. Environmental and Molecular Mutagenesis. 57:706-716.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  I. Chemical reduction and mitigation of mutagenicity. Toxicology and Applied Pharmacology. 306:113-119.

Kirman CR, Suh M, Hays SM, Gürleyük H, Gerads R, De Flora S, Parker W, Lin S, Haws LC, Harris MA, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  II. Ex vivo gastric reduction modeling. Toxicology and Applied Pharmacology. 306:120-133.

Cullen JM, Ward JM, Thompson CM. 2016. Reevaluation and classification of duodenal lesions in B6C3F1 mice and F344 rats from 4 studies of hexavalent chromium in drinking water. Toxicol. Path. 44(2):279-89.


Proctor DM, Suh M, Mittal L, Hirsch S, Salgado RV, Bartlett C, Van Landingham C, Rohr A, Crump K. 2015. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. J Expo Sci Environ Epidemiol.  doi: 10.1038/jes.2015.77.

Thompson CM, Wolf JC, Elbekai RH, Paranjpe MG, Seiter JM, Chappell MA, Tappero RV, Suh M, Proctor DM, Bichteler A, Haws LC, Harris MA. 2015. Duodenal crypt health following exposure to Cr(VI): Micronucleus scoring, γ-H2AX immunostaining, and synchrotron X-ray fluorescence microscopy. Mut. Res. 789-790 (2015): 61–66.

Thompson, C.M., Young, R.R., Suh, M., Dinesdurage, H.R., Elbekai, R.H., Harris, M.A., Rohr, A.C. and Proctor, D.M. 2015. Assessment of the mutagenic potential of Cr(VI) in the oral mucosa of Big Blue® transgenic F344 rats. Environ. Mol. Mutagen. 56:621-628.

Young, R.R, Thompson, C.M., Dinesdurage, H.R., Elbekai, R.H., Suh, M., Rohr, A.C. and Proctor, D.M. 2015. A robust method for assessing chemically induced mutagenic effects in the oral cavity of transgenic Big Blue® rats. Environ. Mol. Mutagen. 56:629-636.

Thompson CM, Seiter J, Chappell MA, Tappero RV, Proctor DMSuh M, Wolf JC, Haws LC, Vitale R, Mittal L, Kirman CR, Hays SM, Harris MA. 2015. Synchrotron-based imaging of chromium and γ-H2AX immunostaining in the duodenum following repeated exposure to Cr(VI) in drinking water. Toxicol Sci. 143(1): 16-25.


Proctor DM, Suh M. Campleman SL, Thompson CM. 2014. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures. Toxicology 325:160-179.

Suh M, Thompson C, Kirman C, Carakostas M, Haws LC, Harris M, Proctor. 2014. High concentrations of hexavalent chromium in drinking water alter iron homeostasis in F344 rats and B6C3F1 mice. Food and Chemical Toxicology. 65:381-388.


Thompson CM, Kirman CR, Proctor DMHaws LCSuh M, Hays S, Hixon JGHarris MA. 2013. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. Journal of Applied Toxicology. DOI: 10.1002/jat.2907

Kirman CR, Aylward LL, Suh MHarris MAThompson CMHaws LCProctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact. Apr 17. doi:pii: S0009-2797(13)00082-3. 10.1016/j.cbi.2013.04.003.

O’Brien T, Ding H, Suh MThompson C, Parsons BL, Harris MA, Winkelman WA, Wolf JC, Hixon JG, Schwartz AM, Myers MB, Haws LC, Proctor DM. 2013. Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. Mutat Res. Apr 9. pii: S1383-5718(13)00075-2. doi: 10.1016/j.mrgentox.2013.03.008

Thompson CMProctor DMSuh MHaws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Critical Reviews in Toxicology. 43(3): 244-274.


Kirman, CR, Hays, SM, Aylward, LL, Suh, M, Harris, MA, Thompson, CM, Haws, LC, Proctor, DM. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact. 200(1): 45-64.

Kopec, A.K., C.M. Thompson, S. Kim, A.L. Forgacs, T.R. Zacharewski. 2012. Comparative Toxicogenomic Analysis of Oral Cr(VI) Exposure Effects in Rat and Mouse Small Intestinal Epithelium. Toxicol Appl Pharmacol. 262(2): 124-38.

Kopec, A.K., Kim, S., Forgacs, A.L., Zacharewski, T.R., Proctor, D.M., Harris, M.A.Haws, L.CThompson, C.M.2012. Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90 days of exposure to hexavalent chromium in drinking water. Toxicology and Applied Pharmacology. 259(1):13-26.

Proctor, D.M.Suh, M., Aylward, L.L., Kirman, C.R., Harris, M.A.Thompson, C.M., Gürleyük, H., Gerads, R., Haws, L.C., Hays, S.M. 2012. Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere. 89(5): 487-93.

Thompson, C.M., Y. Fedorov, D.D. Brown, M. SuhD.M. Proctor, L. Kuriakose, L.C. Haws, M.A. Harris. 2012. Assessment of Cr(VI)-Induced Cytotoxicity and Genotoxicity Using High Content Analysis. PLoS ONE. 7(8): e42720.

Thompson, C.M., J.G. Hixon, D.M. Proctor, L.C. Haws, M. Suh, J.D. Urban, M.A. Harris. 2012. Assessment of Genotoxic Potential of Cr(VI) in the Mouse Duodenum: An In Silico Comparison with Mutagenic and Nonmutagenic Carcinogens Across Tissues. Regul Toxicol Pharmacol. 64(1): 68-76.

Thompson, C.M.D.M. ProctorM. SuhL.C. Haws, C.D. Hebert, J.F. Mann, H.G. Shertzer, J.G. Hixon and M.A. Harris. 2012. Comparison of the Effects of Hexavalent Chromium in the Alimentary Canal of F344 Rats and B6C3F1 Mice Following Exposure in Drinking Water: Implications for Carcinogenic Modes of Action. Toxicol Sci. 125(1):79-90.

Thompson, C.M.D.M. Proctor,and M.A. Harris. 2012. Duodenal GSH/GSSG Ratios in Mice Following Oral Exposure to Cr(VI). Toxicol Sci. 126(1): 287-288.


Thompson, C.M., D.M. Proctor, L.C. Haws, C.D. Hebert, S.D. Grimes, H.G. Shertzer, A.K. Kopec, J.G. Hixon, T.R. Zacharewski and M.A. Harris. 2011. Investigation of the Mode of Action Underlying the Tumorigenic Response Induced in B6C3F1 Mice Exposed Orally to Hexavalent Chromium. Toxicol Sci. 123(1): 58-70.

Thompson, C.M., L.C. Haws, M.A. Harris, N.M. Gatto and D.M. Proctor. 2011. Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium. Toxicol Sci. 119(1): 20-40.